<SEC-DOCUMENT>0001437749-22-018991.txt : 20220804
<SEC-HEADER>0001437749-22-018991.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804213044
ACCESSION NUMBER:		0001437749-22-018991
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220705
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			NOUGUES MAXIMO F
		CENTRAL INDEX KEY:			0001758507

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35703
		FILM NUMBER:		221138378

	MAIL ADDRESS:	
		STREET 1:		C/O PUMA BIOTECHNOLOGY, INC.
		STREET 2:		10880 WILSHIRE BOULEVARD, SUITE 2150
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90024

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PUMA BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0001401667
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770683487
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		10880 WILSHIRE BLVD.
		STREET 2:		SUITE 2150
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90024
		BUSINESS PHONE:		(424) 248-6500

	MAIL ADDRESS:	
		STREET 1:		10880 WILSHIRE BLVD.
		STREET 2:		SUITE 2150
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INNOVATIVE ACQUISITIONS CORP
		DATE OF NAME CHANGE:	20070601
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>rdgdoc.xml
<DESCRIPTION>FORM 4/A
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2022-07-05</periodOfReport>

    <dateOfOriginalSubmission>2022-07-07</dateOfOriginalSubmission>

    <issuer>
        <issuerCik>0001401667</issuerCik>
        <issuerName>PUMA BIOTECHNOLOGY, INC.</issuerName>
        <issuerTradingSymbol>PBYI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001758507</rptOwnerCik>
            <rptOwnerName>NOUGUES MAXIMO F</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PUMA BIOTECHNOLOGY, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>10880 WILSHIRE BLVD., SUITE 2150</rptOwnerStreet2>
            <rptOwnerCity>LOS ANGELES</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>90024</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOfficer>1</isOfficer>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-07-05</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>9328</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>2.6315</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>111738</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.</footnote>
    </footnotes>

    <remarks>On July 7, 2022, the Reporting Person filed a Form 4 which inadvertently reported that 5,835 shares of Common Stock were disposed in the transaction, following which a total of 64,625 shares of Common Stock were beneficially owned by the Reporting Person.  In fact, as reported in this amendment, the Reporting Person disposed of 9,328 shares of Common Stock, following which the Reporting Person directly owned 111,738 shares of Common Stock.</remarks>

    <ownerSignature>
        <signatureName>/s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues</signatureName>
        <signatureDate>2022-08-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
